688656 浩欧博
已收盘 09-18 15:00:01
资讯
新帖
简况
浩欧博（688656）披露2025年第三次临时股东大会会议资料，9月17日股价上涨5.0%
证券之星 · 09-17 22:13
浩欧博（688656）披露2025年第三次临时股东大会会议资料，9月17日股价上涨5.0%
每周股票复盘：浩欧博（688656）拟为高管购责险最高5000万
证券之星 · 09-14
每周股票复盘：浩欧博（688656）拟为高管购责险最高5000万
每周股票复盘：浩欧博（688656）变更审计机构及补选独董
证券之星 · 09-07
每周股票复盘：浩欧博（688656）变更审计机构及补选独董
9月4日浩欧博涨6.45%，农银医疗保健股票基金重仓该股
证券之星 · 09-04
9月4日浩欧博涨6.45%，农银医疗保健股票基金重仓该股
每周股票复盘：浩欧博（688656）完成要约收购股份交割
证券之星 · 08-31
每周股票复盘：浩欧博（688656）完成要约收购股份交割
8月25日浩欧博跌9.01%，农银医疗保健股票基金重仓该股
证券之星 · 08-25
8月25日浩欧博跌9.01%，农银医疗保健股票基金重仓该股
每周股票复盘：浩欧博（688656）召开股东大会变更审计机构及补选独立董事
证券之星 · 08-24
每周股票复盘：浩欧博（688656）召开股东大会变更审计机构及补选独立董事
8月22日浩欧博涨9.70%，农银医疗保健股票基金重仓该股
证券之星 · 08-22
8月22日浩欧博涨9.70%，农银医疗保健股票基金重仓该股
8月21日浩欧博涨8.42%，农银医疗保健股票基金重仓该股
证券之星 · 08-21
8月21日浩欧博涨8.42%，农银医疗保健股票基金重仓该股
浩欧博（688656）2025年中报简析：净利润减39.1%，公司应收账款体量较大
证券之星 · 08-16
浩欧博（688656）2025年中报简析：净利润减39.1%，公司应收账款体量较大
浩欧博(688656.SH)发布半年度业绩，归母净利润1217万元，同比下降39.1%
智通财经 · 08-14
浩欧博(688656.SH)发布半年度业绩，归母净利润1217万元，同比下降39.1%
医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道
国金证券 · 08-10
医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道
每周股票复盘：浩欧博（688656）全资子公司获3项医疗器械注册证
证券之星 · 08-10
每周股票复盘：浩欧博（688656）全资子公司获3项医疗器械注册证
浩欧博：产品“葎草（W22）过敏原特异性IgE抗体检测试剂盒”取得注册证
每日经济新闻 · 08-04
浩欧博：产品“葎草（W22）过敏原特异性IgE抗体检测试剂盒”取得注册证
浩欧博最新公告：拟出售土地使用权、厂房建筑物
证券之星 · 08-04
浩欧博最新公告：拟出售土地使用权、厂房建筑物
浩欧博：全资子公司获得3项医疗器械注册证
格隆汇 · 08-04
浩欧博：全资子公司获得3项医疗器械注册证
浩欧博股价下跌5.27% 政策扰动与业绩承压共振
智选洞察 · 08-04
浩欧博股价下跌5.27% 政策扰动与业绩承压共振
浩欧博股价下跌5.02% 医疗器械集采预期加剧资金抛压
智选洞察 · 07-17
浩欧博股价下跌5.02% 医疗器械集采预期加剧资金抛压
累计对外授权近300亿后，上海“创新药黑马”拟易主，中生制药超35亿收购礼新医药
时代周报 · 07-16
累计对外授权近300亿后，上海“创新药黑马”拟易主，中生制药超35亿收购礼新医药
浩欧博股价下跌6.11% 医疗器械集采预期深化叠加资金流出
智选洞察 · 07-16
浩欧博股价下跌6.11% 医疗器械集采预期深化叠加资金流出
加载更多
公司概况
公司名称：
江苏浩欧博生物医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-01-13
主营业务：
江苏浩欧博生物医药股份有限公司的主营业务是体外诊断试剂的研发、生产和销售。公司的主要产品是IgE检测、食物特异性IgG检测、自免产品。
发行价格：
35.26
{"stockData":{"symbol":"688656","market":"SH","secType":"STK","nameCN":"浩欧博","latestPrice":171,"timestamp":1758178801000,"preClose":168.52,"halted":0,"volume":1375022,"delay":0,"changeRate":0.0147,"floatShares":63479700,"shares":63479700,"eps":0.4568,"marketStatus":"已收盘","change":2.48,"latestTime":"09-18 15:00:01","open":167.59,"high":172.8,"low":162,"amount":232000000,"amplitude":0.0641,"askPrice":171,"askSize":40,"bidPrice":170.88,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.4568,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1758245400000},"marketStatusCode":5,"adr":0,"adjPreClose":168.52,"symbolType":"stock_kcb","openAndCloseTimeList":[[1758159000000,1758166200000],[1758171600000,1758178800000]],"highLimit":185.37,"lowLimit":151.67,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":63479740,"isCdr":false,"pbRate":13.33,"roa":"--","peRate":374.343257,"roe":"1.49%","epsLYR":0.59,"committee":-0.366197,"marketValue":10855000000,"turnoverRate":0.0217,"status":0,"afterMarket":{"amount":0,"volume":0,"close":171,"buyVolume":591,"sellVolume":0,"time":1758180839260,"indexStatus":"已收盘 09-18 15:30:00","preClose":168.52},"floatMarketCap":10855000000},"requestUrl":"/m/hq/s/688656","defaultTab":"news","newsList":[{"id":"2568531492","title":"浩欧博（688656）披露2025年第三次临时股东大会会议资料，9月17日股价上涨5.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568531492","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568531492?lang=zh_cn&edition=full","pubTime":"2025-09-17 22:13","pubTimestamp":1758118400,"startTime":"0","endTime":"0","summary":"截至2025年9月17日收盘，浩欧博报收于168.52元，较前一交易日上涨5.0%，最新总市值为106.98亿元。该股当日开盘161.0元，最高173.0元，最低155.13元，成交额达2.72亿元，换手率为2.61%。近日，江苏浩欧博生物医药股份有限公司发布2025年第三次临时股东大会会议资料。公告显示，公司将于2025年9月25日召开第三次临时股东大会，审议两项议案。会议采取现场与网络投票相结合方式表决。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700040300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2567113524","title":"每周股票复盘：浩欧博（688656）拟为高管购责险最高5000万","url":"https://stock-news.laohu8.com/highlight/detail?id=2567113524","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567113524?lang=zh_cn&edition=full","pubTime":"2025-09-14 04:08","pubTimestamp":1757794095,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，浩欧博报收于166.0元，较上周的129.73元上涨27.96%。本周，浩欧博9月12日盘中最高价报175.0元，股价触及近一年最高点。本周关注点公司公告汇总：浩欧博拟为董事、监事及高管购买责任保险，责任限额不超过5000万元。公司公告汇总江苏浩欧博生物医药股份有限公司第三届监事会第二十一次会议于2025年9月9日召开，审议通过《关于为董事、监事及高级管理人员购买责任保险的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400000924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2565543482","title":"每周股票复盘：浩欧博（688656）变更审计机构及补选独董","url":"https://stock-news.laohu8.com/highlight/detail?id=2565543482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565543482?lang=zh_cn&edition=full","pubTime":"2025-09-07 05:22","pubTimestamp":1757193737,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，浩欧博报收于129.73元，较上周的123.68元上涨4.89%。本周，浩欧博9月4日盘中最高价报139.98元。本周关注点公司公告汇总：浩欧博2025年第二次临时股东大会审议通过变更2025年度审计机构的议案，同意票占比99.9829%。公司公告汇总：浩欧博补选钱世政、彭建刚为第三届董事会独立董事，得票率均超99.75%。出席会议股东37人，代表表决权股份43,224,978股，占公司总表决权68.9630%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700001032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2564532322","title":"9月4日浩欧博涨6.45%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564532322","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564532322?lang=zh_cn&edition=full","pubTime":"2025-09-04 16:29","pubTimestamp":1756974585,"startTime":"0","endTime":"0","summary":"证券之星消息，9月4日浩欧博涨6.45%，收盘报132.54元，换手率6.26%，成交量3.98万手，成交额5.29亿元。重仓浩欧博的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090400025336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2563832139","title":"每周股票复盘：浩欧博（688656）完成要约收购股份交割","url":"https://stock-news.laohu8.com/highlight/detail?id=2563832139","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563832139?lang=zh_cn&edition=full","pubTime":"2025-08-31 14:54","pubTimestamp":1756623250,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，浩欧博报收于123.68元，较上周的137.8元下跌10.25%。本周关注点公司公告汇总：浩欧博要约收购股份于2025年2月14日完成交割。公司公告汇总中国国际金融股份有限公司作为财务顾问，发布了关于双润正安信息咨询（北京）有限公司要约收购江苏浩欧博生物医药股份有限公司2025年第二季度持续督导意见。2025年1月24日，浩欧博公告要约收购结果，最终接受要约的股份为14,326,151股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100004979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2562211457","title":"8月25日浩欧博跌9.01%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2562211457","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562211457?lang=zh_cn&edition=full","pubTime":"2025-08-25 16:27","pubTimestamp":1756110460,"startTime":"0","endTime":"0","summary":"证券之星消息，8月25日浩欧博跌9.01%，收盘报125.39元，换手率6.85%，成交量4.35万手，成交额5.67亿元。重仓浩欧博的前十大公募基金请见下表：根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500021721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2561258339","title":"每周股票复盘：浩欧博（688656）召开股东大会变更审计机构及补选独立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2561258339","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561258339?lang=zh_cn&edition=full","pubTime":"2025-08-24 04:14","pubTimestamp":1755980055,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘，浩欧博报收于137.8元，较上周的112.9元上涨22.05%。本周，浩欧博8月22日盘中最高价报139.98元。浩欧博当前最新总市值87.48亿元，在医疗器械板块市值排名46/126，在两市A股市值排名2115/5152。本周关注点公司公告汇总：浩欧博将于2025年9月1日召开第二次临时股东大会，主要审议变更审计机构和补选独立董事的议案公司公告汇总江苏浩欧博生物医药股份有限公司将于2025年9月1日召开第二次临时股东大会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400000761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2561424343","title":"8月22日浩欧博涨9.70%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2561424343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561424343?lang=zh_cn&edition=full","pubTime":"2025-08-22 16:22","pubTimestamp":1755850942,"startTime":"0","endTime":"0","summary":"证券之星消息，8月22日浩欧博涨9.70%，收盘报137.8元，换手率6.93%，成交量4.4万手，成交额5.96亿元。重仓浩欧博的前十大公募基金请见下表：根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200028967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2561452734","title":"8月21日浩欧博涨8.42%，农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2561452734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561452734?lang=zh_cn&edition=full","pubTime":"2025-08-21 16:11","pubTimestamp":1755763919,"startTime":"0","endTime":"0","summary":"证券之星消息，8月21日浩欧博涨8.42%，收盘报125.62元，换手率5.09%，成交量3.23万手，成交额4.03亿元。重仓浩欧博的前十大公募基金请见下表：根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为农银汇理基金的农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100026060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2559949082","title":"浩欧博（688656）2025年中报简析：净利润减39.1%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2559949082","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559949082?lang=zh_cn&edition=full","pubTime":"2025-08-16 06:04","pubTimestamp":1755295490,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期浩欧博发布2025年中报。截至本报告期末，公司营业总收入1.9亿元，同比下降6.48%，归母净利润1216.92万元，同比下降39.1%。本报告期浩欧博公司应收账款体量较大，当期应收账款占最新年报归母净利润比达148.04%。本次财报公布的各项数据指标表现不尽如人意。去年的净利率为9.15%，算上全部成本后，公司产品或服务的附加值一般。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081600004319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656"],"gpt_icon":0},{"id":"2559954307","title":"浩欧博(688656.SH)发布半年度业绩，归母净利润1217万元，同比下降39.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559954307","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559954307?lang=zh_cn&edition=full","pubTime":"2025-08-14 19:40","pubTimestamp":1755171630,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浩欧博(688656.SH)披露2025年半年度报告，报告期公司实现营收1.9亿元，同比下降6.48%;归属于上市公司股东的净利润1217万元，同比下降39.1%;扣非净利润1036万元，同比下降45.46%;基本每股收益0.19元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1329742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688656"],"gpt_icon":0},{"id":"2558835566","title":"医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道","url":"https://stock-news.laohu8.com/highlight/detail?id=2558835566","media":"国金证券","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558835566?lang=zh_cn&edition=full","pubTime":"2025-08-10 12:06","pubTimestamp":1754798792,"startTime":"0","endTime":"0","summary":"投资逻辑国内政策叠加资本双重支持，行业迎来重大发展机遇。近年来国内政策端对脑机接口行业支持力度较高，支持性政策在产品注册、医保支付、行业标准等层面均有体现。1）在产品注册方面，国家药监局将配合相关部门出台基于脑机接口技术的医疗器械产品支持政策，脑机接口相关产品有望通过创新器械绿色通道实现更快注册审批。其中医疗健康领域仍是脑机接口应用最大的细分领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081012063594da7295&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081012063594da7295&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688236","688212","603987","603222","688151","603309","688085","605369","688271","688068","688575","688277","688580","603014","688576","688013","688607","600807","688468","600587","688108","560260","688114","688139","600055","603387","688389","603205","688029","688273","688606","688050","688067","688656","688677","688351","688393","688314","688016","688366","603976","688301","688317","600645","159883","688026","688161","688193","600529","688198","688217","688289","688298","688358","688253","688581","688613","603658","688075","688426","603880","688338","688410","688617","688755","688767"],"gpt_icon":0},{"id":"2558507926","title":"每周股票复盘：浩欧博（688656）全资子公司获3项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2558507926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558507926?lang=zh_cn&edition=full","pubTime":"2025-08-10 02:35","pubTimestamp":1754764513,"startTime":"0","endTime":"0","summary":"截至2025年8月8日收盘，浩欧博报收于111.89元，较上周的121.4元下跌7.83%。本周，浩欧博8月4日盘中最高价报121.4元。本周关注点公司公告汇总: 浩欧博全资子公司获得3项医疗器械注册证，涉及过敏原特异性IgE抗体检测试剂盒公司公告汇总: 浩欧博拟1952万元出售位于苏州工业园区的土地使用权及厂房建筑物公司公告汇总江苏浩欧博生物医药股份有限公司全资子公司湖南浩欧博生物医药有限公司获得湖南省药品监督管理局核准签发的3项医疗器械注册证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081000000414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09997","09996","BK1100","159883","BK1574","BK1583","688656","BK1222","BK0239"],"gpt_icon":0},{"id":"2556388377","title":"浩欧博：产品“葎草（W22）过敏原特异性IgE抗体检测试剂盒”取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2556388377","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556388377?lang=zh_cn&edition=full","pubTime":"2025-08-04 17:41","pubTimestamp":1754300517,"startTime":"0","endTime":"0","summary":"每经AI快讯，浩欧博（SH 688656，收盘价：120.29元）8月4日晚间发布公告称，江苏浩欧博生物医药股份有限公司全资子公司湖南浩欧博生物医药有限公司于近日获得湖南省药品监督管理局核准签发的3项医疗器械注册证。包括“葎草（W22）过敏原特异性IgE抗体检测试剂盒”等产品。2024年1至12月份，浩欧博的营业收入构成为：医疗器械占比97.39%，其他业务占比2.61%。截至发稿，浩欧博市值为76亿元。每经头条（nbdtoutiao）——“我们也深陷残酷价格战”！德资巨头中国区高管警告：智驾绝不能免费，否则会给全行业带来灾难（记者 曾健辉）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080417442497328152&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080417442497328152&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2556807908","title":"浩欧博最新公告：拟出售土地使用权、厂房建筑物","url":"https://stock-news.laohu8.com/highlight/detail?id=2556807908","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556807908?lang=zh_cn&edition=full","pubTime":"2025-08-04 17:40","pubTimestamp":1754300406,"startTime":"0","endTime":"0","summary":"浩欧博(688656.SH)公告称，公司拟向苏州芯联成软件有限公司有限公司出售公司拥有的位于江苏省苏州市苏州工业园区星湖街218号17幢（C6栋）的土地使用权、厂房建筑物，经双方协商，本次转让价格预计为1952万元（含税）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080400024357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2556103802","title":"浩欧博：全资子公司获得3项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2556103802","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556103802?lang=zh_cn&edition=full","pubTime":"2025-08-04 17:33","pubTimestamp":1754300022,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1100","BK0239","399441","09997","161726","09996","688656","BK1574","BK1583","159883","BK1222"],"gpt_icon":0},{"id":"2556874231","title":"浩欧博股价下跌5.27% 政策扰动与业绩承压共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2556874231","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556874231?lang=zh_cn&edition=full","pubTime":"2025-08-04 09:52","pubTimestamp":1754272355,"startTime":"0","endTime":"0","summary":"浩欧博股价大幅下跌，最新价115.00元/股，跌幅5.27%。政策扰动与业绩承压共振浩欧博近期股价波动与政策预期及资金博弈密切相关。7月24日医保局提出“反内卷”集采原则后，公司核心产品过敏试剂面临降价压力，叠加2025年一季度营收同比下滑9.33%、净利润降幅达56.97%，业绩压力加速资金离场。估值重构依赖业绩验证长期看，浩欧博的高估值消化需业绩改善与产品创新双轮驱动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804095244a6d13bb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804095244a6d13bb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2552057931","title":"浩欧博股价下跌5.02% 医疗器械集采预期加剧资金抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=2552057931","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552057931?lang=zh_cn&edition=full","pubTime":"2025-07-17 14:34","pubTimestamp":1752734060,"startTime":"0","endTime":"0","summary":"7月17日，浩欧博股价大幅下跌，截至14点33分，最新价为130.00元/股，跌幅5.02%。资金博弈与政策扰动共振浩欧博近期股价剧烈波动与资金面高频切换密切相关。政策面上，医疗器械集采预期持续发酵，导致高估值医药股承压，叠加市场避险情绪升温，加剧了板块资金调仓动作。2025年一季报显示，营收同比下滑9.33%，净利润降幅达56.97%，核心产品过敏试剂收入占比超52%，集采政策可能持续挤压利润空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717143426a6af0eb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717143426a6af0eb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159883","BK0239","688656"],"gpt_icon":0},{"id":"2551414421","title":"累计对外授权近300亿后，上海“创新药黑马”拟易主，中生制药超35亿收购礼新医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2551414421","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551414421?lang=zh_cn&edition=full","pubTime":"2025-07-16 17:44","pubTimestamp":1752659092,"startTime":"0","endTime":"0","summary":"7月15日晚间，中生制药对外宣布，其将以约5亿美元的净代价收购礼新医药95.09%股权。加上此前持有的4.91%股权，此次交易完成后，礼新医药将成为中生制药间接全资附属公司。截至目前，礼新医药累计对外授权近40亿美元，折合人民币近300亿元。这并非中生制药与礼新医药的首次牵手。近年来，传统药企正在加速向创新药方向转型，中生制药也不例外。交易完成后，浩欧博将成为中生制药旗下第一家A股上市公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071617451997a84632&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071617451997a84632&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","01177","BK0239","688656","159938"],"gpt_icon":0},{"id":"2551497116","title":"浩欧博股价下跌6.11% 医疗器械集采预期深化叠加资金流出","url":"https://stock-news.laohu8.com/highlight/detail?id=2551497116","media":"智选洞察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551497116?lang=zh_cn&edition=full","pubTime":"2025-07-16 09:31","pubTimestamp":1752629488,"startTime":"0","endTime":"0","summary":"浩欧博股价大幅下跌，最新价146.00元/股，跌幅6.11%。资金博弈与政策扰动共振浩欧博近期股价波动主要源于资金面的高频切换与政策预期扰动。医疗器械集采预期深化导致板块估值承压，叠加市场避险情绪升温，资金对高估值医药股调仓动作频繁。业绩修复与估值压力并存长期来看，浩欧博面临业绩与估值的双重考验。当前动态市盈率达274.94倍，市净率11.86倍，显著高于医疗器械行业均值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716093619a6ac36fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716093619a6ac36fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159883","688656"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1758228039230,"stockEarnings":[{"period":"1week","weight":0.1672},{"period":"1month","weight":0.4876},{"period":"3month","weight":0.6765},{"period":"6month","weight":0.9283},{"period":"1year","weight":6.6122},{"period":"ytd","weight":0.7967}],"compareEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":0.028},{"period":"3month","weight":0.1404},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.4101},{"period":"ytd","weight":0.1432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏浩欧博生物医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"3114人(较上一季度增加1.60%)","perCapita":"20385股","listingDate":"2021-01-13","address":"江苏省苏州市虎丘区中国(江苏)自由贸易试验区苏州片区苏州工业园区东堰里路9号","registeredCapital":"6347万元","survey":" 江苏浩欧博生物医药股份有限公司的主营业务是体外诊断试剂的研发、生产和销售。公司的主要产品是IgE检测、食物特异性IgG检测、自免产品。","listedPrice":35.26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"浩欧博(688656)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供浩欧博(688656)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"浩欧博,688656,浩欧博股票,浩欧博股票老虎,浩欧博股票老虎国际,浩欧博行情,浩欧博股票行情,浩欧博股价,浩欧博股市,浩欧博股票价格,浩欧博股票交易,浩欧博股票购买,浩欧博股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"浩欧博(688656)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供浩欧博(688656)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}